Oral cicaprost reduces platelet and neutrophil activation in experimental hypercholesterolemia.
Oral treatment of cholesterol-fed rabbits with the PGI2 mimetic cicaprost largely reduces hypercholesterolemia-induced platelet and neutrophil hyperreactivity. In addition, cicaprost prevents atherosclerosis-induced platelet desensitization for PGI2. These effects persist after cicaprost treatment is withdrawn. Since platelets and leukocytes are supposed to contribute to atherogenesis, this suggests a favourable effect of long-term oral PGI2 substitution in hypercholesterolemia.